An interventional study of Culturally and linguistically tailored onboarding and support program and Medtronic MiniMed 780G Insulin Pump System in Diabetes Mellitus, Type 1 Diabetes, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 10 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 39th largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 58th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–89
University of Colorado, Denver · Sites in United States
Ages 14–19
University of Colorado, Denver · Sites in United States
Ages 14–26
University of Colorado, Denver · Sites in United States
Ages 2–26
University of Colorado, Denver · Sites in United States
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 10 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 8
First in 1993; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 44 across the 44 interventional studies, 85 across the 14 observational. Of the 43 that completed or were terminated, 19 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
6 of the studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05819138Phase 3University of Colorado, DenverType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | 2027-10-01 |
| NCT07494188University of Colorado, DenverSleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center | 2026-12-01 |
| NCT07011147University of Colorado, DenverPrimary Care Pragmatic, Real World Experience for Automated Insulin Delivery | 2027-06-30 |
| NCT05319990University of Colorado, DenverPathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) | 2027-06-30 |
| NCT07720388University of Colorado, DenverSupporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study plans to learn more about whether a support program delivered in Spanish or both English and Spanish for bilingual families helps Latino youth with Type 1 Diabetes (T1D) successfully use the Medtronic MiniMed 780G system.
The main question it aims to answer is:
Does a linguistically and culturally tailored onboarding model for an automated insulin delivery system close the gap in technology adoption and improve health outcomes?
Participants will:
This interventional, single-group study will assess the effectiveness of a structured, culturally tailored onboarding and support program designed to promote initiation and sustained use of the Medtronic MiniMed 780G system among Latino/Hispanic youth with type 1 diabetes. Participants will transition to the Medtronic MiniMed 780G system and receive ongoing education and support over an 8-month period. The primary outcome is the proportion of participants continuing use of the system at 6 months. Secondary outcomes include clinical measures derived from routine care (HbA1c, time in range, hypoglycemia) and participant-reported satisfaction and confidence with diabetes technology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Culturally and linguistically tailored onboarding and support program · Device: Medtronic MiniMed 780G Insulin Pump System
The intervention is a structured, eight-month, culturally and linguistically tailored onboarding and support program for the Medtronic MiniMed 780G system. This includes: * Utilization of the Medtronic MiniMed 780G Automated Insulin Delivery system * One-on-one nutrition support with a Registered Dietitian * A pump start class conducted in Spanish or both English and Spanish for bilingual participants by a Certified Diabetes Educator * Virtual check-ins between the participant and study coordinator
Participants will receive a Medtronic MiniMed 780G Automated Insulin Delivery system, an FDA-approved advanced hybrid closed-loop insulin delivery system that integrates with continuous glucose monitoring technology. A unique feature of the device is its availability with a Spanish-language menu and user interface, which may improve accessibility for Spanish-speaking users and families. Participants will complete standard pump onboarding and training and will use the system as part of their routine diabetes management for up to 8 months.
Proportion of Participants Continuing Use of the Medtronic MiniMed 780G System at 6 Months
Adoption will be defined as continued use of the Medtronic MiniMed 780G insulin pump system at 6 months following initiation. The outcome will be calculated as the proportion of enrolled participants who remain actively using the system at the 6-month time point.
Time frame: 6 months
Change from Baseline in Hemoglobin A1c
Hemoglobin A1c (HbA1c) values will be obtained from routine clinical care (standard-of-care laboratory assessments) and not collected as part of study-specific procedures. The outcome will assess the proportion of participants achieving a reduction of greater than or equal to 0.5 percent from baseline.
Time frame: Baseline and 8 months
Proportion of Participants Achieving Time in Range (70-180 mg/dL) greater than 60 percent
Continuous glucose monitoring (CGM) data will be obtained from devices used as part of routine clinical care. Time in Range (TIR) is defined as the percentage of time glucose values are between 70-180 mg/dL. Outcome is the proportion of participants achieving greater than 60 percent TIR.
Time frame: Baseline and 8 months
Change from Baseline in Participant Diabetes Treatment Satisfaction
Participant diabetes treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc). The DTSQc is a validated questionnaire administered to participants aged 13 years and older. The Treatment Satisfaction (Change) score is calculated by summing items 1, 4, 5, 6, 7, and 8. Scores range from negative 18 to 18, with higher scores indicating greater improvement in treatment satisfaction, lower scores indicating greater deterioration in treatment satisfaction, and 0 indicating no change. Participants younger than 13 years of age will not complete this questionnaire; analyses will be limited to participants aged 13 years and older.
Time frame: Baseline and 8 months
Change from Baseline in Participant Confidence in Diabetes Technology Use
Participant confidence in diabetes technology use will be assessed qualitatively through discussions conducted during virtual check-ins. Responses will be analyzed using thematic analysis to identify recurring themes related to confidence in technology use, onboarding experiences, troubleshooting, perceived support needs, language-related challenges, and barriers and facilitators to successful insulin pump adoption. Themes will be summarized descriptively to inform development of a culturally and linguistically tailored insulin pump onboarding program.
Time frame: Baseline through Month 8
Change from Baseline in Caregiver Diabetes Treatment Satisfaction
Caregiver diabetes treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) completed by caregivers of enrolled minor participants. The Treatment Satisfaction (Change) score is calculated by summing items 1, 4, 5, 6, 7, and 8. Scores range from -18 to +18, with higher scores indicating greater improvement in treatment satisfaction, lower scores indicating greater deterioration in treatment satisfaction, and 0 indicating no change.
Time frame: Baseline and 8 months
Change from Baseline in Caregiver Confidence in Diabetes Technology Use
Caregiver confidence in supporting diabetes technology use will be assessed qualitatively through discussions conducted during virtual check-ins with caregivers of enrolled minor participants. Responses will be analyzed using thematic analysis to identify recurring themes related to confidence in supporting insulin pump use, onboarding experiences, troubleshooting, perceived support needs, language-related challenges, and barriers and facilitators to successful insulin pump adoption. Themes will be summarized descriptively to inform development of a culturally and linguistically tailored insulin pump onboarding program.
Time frame: Baseline through Month 8
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 9 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Aug 2026 → Oct 2026, primary completion Jan 2027 → Jul 2027 and completion Mar 2027 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →